Wall Street Analysts Say This Quantum Computing Stock Could Soar 92% in 2026

D-Wave's Advantage2 product drove a sharp revenue inflection in 2025, with sales up 235% through the first nine months to $21.8 million and analysts forecasting full-year 2025 revenue of $25.5 million and $39.5 million in 2026. The company has expanded commercial traction with larger deal sizes including a high-six-figure airline contract and a multiyear €10 million research-facility deal, but it remains unprofitable — adjusted EBITDA losses widened 15% year-to-date — and trades at an aggressive ~335x forward revenue. All 14 covering analysts rate the stock a buy, with a high target of $48 and median $40, implying material upside, though the business remains highly speculative given ongoing operating losses and competitive technology risk.

Analysis

Market structure: D‑Wave (QBTS) is turning annealing from R&D into a commercial niche — direct beneficiaries include QBTS, cloud hosts/ISVs that package Advantage2, and B2B optimization customers (airlines, logistics). Gate‑based pure‑plays (e.g., RGTI) and early-stage hardware vendors are the clear losers for near‑term commercial spend because customers prefer lower‑error, power‑efficient annealing for optimization. The bigger dynamic: larger multi‑year deals (high‑six‑figure to €10m) shift pricing power toward vendors who can promise enterprise SLAs and integration, tightening supply of vetted quantum services and lifting implied vol in equity and option markets.

Risk assessment: Key tail risks — a material cash raise (dilution) within 12 months, loss/postponement of any €5–10m anchor contract, or a gate‑based technical breakthrough that materially compresses annealing’s TAM. Near term (days–weeks) expect headline-driven swings; short term (Q1–Q2 2026) the stock will track quarterly bookings and FY2026 revenue beat/miss vs consensus ($39.5m). Hidden dependencies include revenue concentration (a few large deals), European research partnerships (regulatory/customs risk), and continued R&D spend; catalysts are contract announcements, quarterly results, and any public performance benchmarks for Advantage2.

Trade implications: For tactical exposure, size speculative long QBTS at 1–3% of portfolio with a 12–18 month horizon, targeting analysts’ median upside to $40 (≈+~92% vs some highs) but cap downside with a 25–30% stop or 25% OTM protective put. Pair trade: long QBTS (1%) vs short RGTI (0.5–1%) to express annealing vs gate‑based dispersion; exit if QBTS revenue guide misses by >10% or RGTI reports a material gate‑based breakthrough. Options: buy Jan‑2027 LEAP calls (strike ≈$40) sized to 0.5–1% notional or buy a 12‑month call spread (buy near‑the‑money, sell at 2x premium) to limit capital at risk.

Contrarian angles: Consensus underweights dilution and execution risk — 335x forward P/S implies near‑perfect execution; if cash runway <12 months or Q1–Q2 2026 bookings slip by >15% the multiple can compress >50% quickly. Historical parallels: early commercial cloud/SaaS firms showed that strong initial enterprise contracts didn’t prevent multi‑year losses and heavy dilution; therefore don’t treat recent contracts as de‑risking unless recurring revenue >50% and gross margins improve. Unintended consequence: ramping sales and R&D simultaneously can increase burn and push a follow‑on offering that resets risk/reward — trim to half size on a secondary offering announcement.

Key Decisions for Investors

• Establish a 1–3% long position in QBTS with a 12–18 month horizon; place a hard 25–30% stop or buy a 25% OTM protective put (9–12 month) to limit downside. Exit if FY2026 revenue guide misses consensus ($39.5M) by >10% or if company announces a follow‑on equity raise within 12 months.
• Implement a relative‑value pair: long QBTS (1% net exposure) and short RGTI (0.5–1%) sized to hedge sector beta; unwind if QBTS wins >100% or if RGTI reports consistent commercial traction (two consecutive quarters of >50% YoY recurring revenue growth).
• Buy Jan‑2027 LEAP calls on QBTS (strike ≈$40) sized to 0.5–1% notional, or if premium prohibitive, buy a 12‑month call spread (buy near‑the‑money / sell strike ~2x) to cap loss. Close positions if QBTS reports a >10% miss in quarterly bookings or if cash runway disclosure indicates <12 months without committed financing.
• Reduce exposure to speculative gate‑based small caps (e.g., RGTI) by 1–2% and reallocate into quantum software integrators or cloud providers that host D‑Wave workloads; rotate if sector implied volatility compresses by >20% or if NVDA/AI hardware stocks outperform by >15% over 3 months.